Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
05:52:46 EDT Fri 19 Apr 2024
Enter Symbol
or Name
USA
CA



Q:ASLN - ASLAN PHARMACEUTICALS LIMITED SPON ADS EACH REP 25 ORD SHS ( - http://aslanpharma.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
ASLN - Q0.20.52·0.534.80.54+0.04910.0303.81414770.491  0.58  0.4914.69  0.392Apr 18Apr 1215 min RT 2¢

Recent Trades - Last 10 of 477
Time ETExPriceChangeVolume
     
     
     
     
     
     
     
     
     
     

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-12 08:00U:ASLNNews ReleaseASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
2024-03-27 08:07U:ASLNNews ReleaseAslan Pharmaceuticals to Present at the 2nd Annual H.C. Wainwright Autoimmune and Inflammatory Disease Virtual Conference: Skin Diseases, Conditions and Disorders
2024-03-12 14:35U:ASLNNews ReleaseASLAN Pharmaceuticals Announces $5 Million Registered Direct Offering
2024-03-11 07:00U:ASLNNews ReleaseASLAN Pharmaceuticals Provides TREK-DX Study Update and Highlights Potential of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients
2024-03-06 07:00U:ASLNNews ReleaseASLAN Pharmaceuticals Announces New Translational Data on Eblasakimab in COPD and Appoints Leading Respiratory Experts as Scientific Advisors
2024-02-29 07:00U:ASLNNews ReleaseASLAN Pharmaceuticals Receives Favorable Opinion From the European Patent Office on Composition of Matter Patent Application for Farudodstat
2024-01-08 06:45U:ASLNNews ReleaseASLAN Pharmaceuticals Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
2024-01-02 07:00U:ASLNNews ReleaseASLAN Pharmaceuticals Announces Participation in January Investor Conferences
2023-12-12 07:00U:ASLNNews ReleaseASLAN Pharmaceuticals Provides Year-End Update on Its Eblasakimab and Farudodstat Programs
2023-11-20 07:00U:ASLNNews ReleaseASLAN Pharmaceuticals to Participate in the 35th Annual Piper Sandler Healthcare Conference
2023-11-03 07:00U:ASLNNews ReleaseASLAN Pharmaceuticals Presents New Data on Eblasakimab in Atopic Dermatitis and COPD Translational Models at the 7th Dermatology Drug Development Summit
2023-10-27 08:00U:ASLNNews ReleaseASLAN Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
2023-10-24 08:00U:ASLNNews ReleaseASLAN Pharmaceuticals to Co-Host KOL Panel Discussion Today on Changes in the Clinical Trial and Treatment Landscape for Atopic Dermatitis
2023-10-18 07:00U:ASLNNews ReleaseASLAN Pharmaceuticals to Co-Host KOL Panel Discussion on Changes in the Clinical Trial and Treatment Landscape for Atopic Dermatitis
2023-10-13 09:30U:ASLNNews ReleaseASLAN Pharmaceuticals Presents New Data From Phase 2b Study of Eblasakimab in Atopic Dermatitis in Late Breaker Presentation at 32nd European Academy of Dermatology and Venereology Congress
2023-09-22 07:00U:ASLNNews ReleaseASLAN Pharmaceuticals Announces Acceptance of Late Breaker Abstract on Eblasakimab Phase 2b Results as Oral Presentation and Three Additional Abstracts at 32nd European Academy of Dermatology and Venereology Congress
2023-09-07 07:00U:ASLNNews ReleaseASLAN Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference
2023-08-11 07:00U:ASLNNews ReleaseASLAN Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
2023-07-06 07:55U:ASLNNews ReleaseEblasakimab Monthly Dosing Shows Potential for Best-In-Class Therapy in Positive Phase 2b Study in Atopic Dermatitis
2023-07-05 16:30U:ASLNNews ReleaseASLAN Pharmaceuticals to Host Webcast on July 6, 2023, to Discuss Phase 2b Topline Data From TREK-AD Trial Evaluating Eblasakimab in Atopic Dermatitis